Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2023 Earnings Conference Call May 15, 2023 8:00 AM ET

Company Participants

Michael Wood - LifeSci Advisors

Chaim Lebovits - President and CEO

Stacy Lindborg - Co-CEO

Alla Patlis - Interim CFO

Kirk Taylor - EVP and Chief Medical Officer

Conference Call Participants

David Bautz - Zacks Small-Cap

Operator

Greetings, and welcome to the Brainstorm Cell Therapeutics First Quarter 2023 Earnings Call. At this time, participants are in a listen-only mode. As a reminder this call is being recorded.

I'd now like to introduce your host for today's call, Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.

Michael Wood

Good morning and thank you for joining us. Earlier today, Brainstorm issued a press release with its financial results for the first quarter of 2023, including a corporate update. Before passing it over to the company management for prepared remarks, I want to remind listeners that this conference call will contain numerous statements, descriptions, forecasts and projections regarding Brainstorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative diseases such as ALS, the sufficiency of the company's existing capital resources for continuing operations in 2023 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support its business planning efforts.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Brainstorm's control, including the risks and uncertainties described from time-to-time in the company's SEC filings. The company's results may differ materially from those projected on today's conference call and the company undertakes no obligation to publicly update any forward-looking statements.

Joining us on the call this morning be Mr. Chaim Lebovits, President and CEO of Brainstorm; Dr. Stacy Lindborg, Co-Chief Executive Officer; and Alla Patlis, Interim Chief Financial Officer. In addition, the Company's Executive VP and Chief Medical Officer, Dr. Kirk Taylor is also on the call and will be available to answer your questions during the Q&A session.

So with that I'd like to turn the call over to Mr. Lebovits. Please go ahead.

Chaim Lebovits

Thank you, Michael. Good morning, and thank you to all of you who have joined us to discuss our Q1 2023 financial results and recent progress.

The most important recent development for Brainstorm was that the FDA notified us that there will be an advisory committee to discuss our BLA. We'll announce the date as soon as we know it.